Related Experiment Video

Updated: Aug 14, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate

B R Lewis1, S L Aoun, G A Bernstein

  • 1Nystrom and Associates, New Brighton, Minnesota 55112, USA.

Journal of Child and Adolescent Psychopharmacology
|July 5, 2001
PubMed

Insights

Drug interactions involving cyclosporine (CSA) were observed in a pediatric heart transplant patient. Bupropion lowered CSA levels, while methylphenidate increased them, highlighting potential risks in young transplant recipients.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Transplantation Medicine

Background:

  • Cyclosporine (CSA) is a critical immunosuppressant following organ transplantation.
  • Managing medication regimens in pediatric transplant patients presents unique challenges.
  • Psychotropic medications are frequently used in children with chronic health conditions.

Observation:

  • A 10-year-old heart transplant recipient experienced significant fluctuations in blood cyclosporine (CSA) levels.
  • Concurrently administered bupropion was associated with a potentially life-threatening decrease in CSA levels.
  • Subsequent administration of methylphenidate led to an increase in CSA levels.

Findings:

  • This case highlights previously undocumented drug-drug interactions between cyclosporine and bupropion in a pediatric patient.
  • A potential interaction between cyclosporine and methylphenidate was also observed in this young transplant recipient.
  • These interactions suggest altered cyclosporine pharmacokinetics influenced by psychotropic medications.

Implications:

  • The findings underscore the need for careful monitoring of cyclosporine levels when co-prescribing bupropion or methylphenidate in pediatric transplant patients.
  • Further research is warranted to elucidate the mechanisms of these drug-drug interactions.
  • Clinicians should consider potential interactions when prescribing psychotropic agents to pediatric transplant recipients on immunosuppressants.

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Diagonal Method to Measure Synergy Among Any Number of Drugs12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...